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OBJECTIVES The study evaluated a nonsurgical means of intramyocardial cell introduction using the
coronary venous system for direct myocardial access and cell delivery.
BACKGROUND Direct myocardial cell repopulation has been proposed as a potential method to treat heart
failure.
METHODS We harvested bone marrow from Yorkshire swine (n  6; 50 to 60 kg), selected culture-flask
adherent cells, labeled them with the gene for green fluorescence protein, expanded them in
culture, and resuspended them in a collagen hydrogel. Working through the coronary sinus,
a specialized catheter system was easily delivered to the anterior interventricular coronary vein.
The composite catheter system (TransAccess) incorporates a phased-array ultrasound tip for
guidance and a sheathed, extendable nitinol needle for transvascular myocardial access. A
microinfusion (IntraLume) catheter was advanced through the needle, deep into remote
myocardium, and the autologous cell–hydrogel suspension was injected into normal heart.
Animals were sacrificed at days 0 (n  2), 14 (n  1,  1 control/collagen biogel only), and
28 (n  2), and the hearts were excised and examined.
RESULTS We gained widespread intramyocardial access to the anterior, lateral, septal, apical, and
inferior walls from the anterior interventicular coronary vein. No death, cardiac tamponade,
ventricular arrhythmia, or other procedural complications occurred. Gross inspection dem-
onstrated no evidence of myocardial perforation, and biogel/black tissue dye was well localized
to sites corresponding to fluoroscopic landmarks for delivery. Histologic analysis demon-
strated needle and microcatheter tracts and accurate cell–biogel delivery.
CONCLUSIONS Percutaneous intramyocardial access is safe and feasible by a transvenous approach through
the coronary venous system. The swine offers an opportunity to refine approaches used for
cellular cardiomyoplasty. (J Am Coll Cardiol 2003;41:1964–71) © 2003 by the American
College of Cardiology Foundation
Nearly 5 million Americans currently live with congestive
heart failure (CHF). This disease accounts for 962,000
hospitalizations and 287,200 deaths annually. In 1998, over
$3.6 billion was paid to Medicare beneficiaries for CHF
expenditures, and the prevalence of this disease continues to
increase (1). Orthotopic cardiac transplantation remains
limited by donor supply, and by need for lifelong immuno-
suppression, invasiveness, and cost. Both cell- and gene-based
therapies have been proposed as potential alternatives for
treatment of this often recalcitrant patient population (2–7).
Current methods of direct cell and gene delivery have
notable limitations. The target patient populations, those
with recent myocardial infarction (MI) or advanced heart
failure, typically are at higher risk for conventional surgical
approaches and for general anesthesia. Furthermore, open
surgical approaches have limited septal wall access. Several
catheter-based methods, including endoventricular (8–11),
intracoronary infusion (12), and coronary vein retroinfusion
(13) are being evaluated. Intracoronary and coronary venous
infusions are less specific than direct injections and may
potentially decrease the therapeutic yield. Endoventricular
methods may have limited access to the myocardium in the
area of the submitral valve apparatus and may be unstable in
the mobile ventricular wall.
We introduce a new concept for direct myocardial access
using the coronary venous system as a roadmap to the heart
(Fig. 1) and a composite catheter system to allow direct and
stable access to remote myocardium (Figs. 2 and 3) with
intravascular ultrasound (IVUS) and fluoroscopic guidance.
This method provides an alternate platform for cell-, gene-,
and drug-based cardiovascular bioengineering therapies
(14). The objective of this study was to test feasibility,
accuracy, and safety (death, cardiac tamponade, sustained
arrhythmia) of this transvenous delivery method.
METHODS
This investigation was approved by the Massachusetts
General Hospital and United States Army Subcommittee
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on Animal Research Care, and was in compliance with the
1996 Guide for the Care and Use of Laboratory Animals
and with the Animal Welfare Act. This study was designed
primarily to assess the safety and feasibility of percutaneous,
trans(coronary)venous, direct myocardial cell delivery using
an engineered substrate of an autologous bone marrow
subpopulation within a biodegradable polymer.
Bone marrow harvest and cell preparation. Six Yorkshire
swine (50 kg) received sedation with intramuscular (IM)
acepromazine 5 mg/atropine 1 mg and intravenous telazol
110 mg/Xylazine 250 mg. Five of the six animals were
subject to bone marrow harvest (the sixth as a negative
control). The iliac crest was accessed with a bone marrow
aspiration needle (MD Tech, Gainesville, Florida), and
50 cc of bone marrow was aspirated into a sterile,
heparinized syringe. These cells were injected through a
50-m filter to exclude large particles and into a 75-cm2
uncoated, vented polystyrene Falcon flask (Corning, Inc.,
Corning, New York). The adherent population was cultured
in high glucose Dulbecco’s Modified Eagle Medium
(GIBCO, Auckland, New Zealand) to 80% to 90% conflu-
ence. This population of adherent cells was intended to be
analogous to the putative mesenchymal stem cell population
(15,16), but was not further characterized for this study.
These adherent cells were distributed to 30% confluence
on six-well plates (Becton Dickson, Franklin Lakes, New
Jersey) and transduced with murine green fluorescence
protein (GFP) using a vesiculostomatitis vector. These cells
were qualitatively assessed under direct fluorescence within
three days for GFP expression. All animals had 70% to 75%
of cells expressing GFP determined by qualitative assess-
ment of two independent observers. The cells were ex-
panded in culture by serial advancement through 25-cm2,
75-cm2, and 150-cm2 Falcon flasks and passaged in 1:2
fashion when 90% confluence was reached.
At the time of procedure, the autologous cells were
recombined and resuspended in 0.3% collagen biogel (Cel-
lagen, ICN Biomedicals, Aurora, Ohio), with the addition
of tissue dye for gross pathologic identification (n 5 pigs).
An aliquot of cells was evaluated for fluorescence using flow
cytometry. This cell–biogel preparation of 2.0  107
cells/ml was divided evenly into 1 cc luer-tipped syringes.
Collagen biogel/tissue dye without cells was used in the
negative control animal.
Trans(coronary)venous myocardial access procedure.
The swine were sedated, ventilated, and monitored (cardiac
rhythm, oxygenation, and blood pressure), and then
prepped and draped in standard surgical fashion. Six French
(F) arterial (Cordis, Miami, Florida) and 14F venous (Trans-
vascular, Menlo Park, California) femoral sheaths were placed
percutaneously. The left main coronary artery was selective-
ly engaged with a 6F Hockeystick diagnostic catheter
(Medtronic) and angiography performed with emphasis on
venous follow-through phases to determine coronary venous
anatomy, anomalies, and coronary sinus location.
Figure 1. The coronary venous system. Coronary veins parallel the major
epicardial coronary arteries, but are free of obstructive disease, and thus can
provide a platform for myocardial access. The anterior, septal, and lateral
walls are drained by branching vessels from the anterior interventricular
coronary vein (AIV) (which parallels the left anterior descending artery),
which drains into the great cardiac vein (GCV) (paralleling the left
circumflex artery) and through the coronary sinus (CS) into the right
atrium. (A) Anterior and (B) posterior views. AIV  anterior interven-
tricular coronary vein; CS  coronary sinus; GCV  great cardiac vein.
Courtesy of Transvascular, Inc.
Abbreviations and Acronyms
AIV  anterior interventricular coronary vein
CHF  congestive heart failure
CS  coronary sinus
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The coronary sinus (CS) was accessed by placing a 7F
Porcine 3 catheter into the right ventricle, withdrawing with
clockwise torque across the tricuspid valve. Using this
technique, the catheter tends to fall into, or near, the CS.
An exchange length, 0.035-inch hydrophilic angled wire
(Teruma) with J-tip was advanced into the CS, through the
great cardiac vein (GCV), and into the anterior interven-
tricular coronary vein (AIV) (Fig. 4A). The diagnostic
catheter was withdrawn, with the guide wire in place, and a
14F CS guiding catheter (Transvascular) and introducer
were placed with conventional over-the-wire technique.
After removal of introducer, a subselective catheter (Trans-
vascular) was then placed over the wire, through the CS
guide, and into the AIV (Fig. 4B). The hydrophilic guide
wire was then exchanged for a 0.014-inch HiTorque floppy
(Guidant, Temecula, California) guide wire. The TransAc-
cess catheter is a 6F, monorail, composite catheter system
combining a phased-array IVUS (compatible with JOMED
IVUS, JOMED, NV) and a pre-shaped, sheathed, extend-
able 24-gauge nitinol needle (Fig. 3A). This TransAccess
catheter was advanced over the 0.014-inch guide wire and
into the AIV in preparation for myocardial access (Fig. 4C).
Intravascular orientation was performed using the corre-
sponding artery, pericardium, and ventricular chamber as
landmarks with IVUS imaging (Figs. 4D and 4E). After
confirmation of position within the coronary vein and with
Figure 2. Transcoronary venous myocardial access can be achieved by intravascular, ultrasound-guided, transvenous needle puncture into targeted areas of
the myocardium (infarct area depicted in gray), providing a stable and accurate platform for direct myocardial therapeutic agent delivery. AIV  anterior
interventricular coronary vein. Courtesy of Transvascular, Inc.
Figure 3. TransAccess composite catheter (A) incorporates phased-array intravascular ultrasound (IVUS) to accurately guide transvenous myocardial
puncture with a sheathed, extendable nitinol needle (black arrow). Once the myocardium is accessed, (B) the IntraLume microinfusion catheter (white
arrow) can be advanced to remote areas of myocardium for targeted therapeutic agent delivery. AIV  anterior interventricular coronary vein; IVUS 
intravascular ultrasound; LAD  left anterior descending coronary artery; OM  obtuse marginal artery; PDA  posterior descending artery; PDV 
posterior descending vein, or middle cardiac vein; PLV  posterolateral vein. Courtesy of Transvascular, Inc.
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Figure 4. Trans(coronary) venous cell delivery. (A) The coronary sinus (CS) is engaged, and a J-tipped hydrophilic guide wire is placed into the anterior
interventricular coronary vein (AIV). (B) The CS and SS guiding catheters are placed using conventional over-the-wire wire technique. (C) The hydrophilic
wire is exchanged for a 0.014-inch guidewire, and the TransAccess catheter is advanced into position. (D,E) IVUS provides anatomic orientation for
transvenous, myocardial puncture into the anterior (D) and septal (E) (IVUS pointer marker delineated by yellow arrows) walls from the AIV with (F) an
extendable nitinol needle (arrows). The IntraLume microinfusion catheter is advanced to targeted areas for cell delivery (G, arrows delineate
contrast-enhanced cell injections). This method allows contiguous “beads” of cell substrate to be placed. AIV  anterior interventricular coronary vein; CS
 coronary sinus; GW  guide wire; IVUS  intravascular ultrasound; LAD  left anterior descending coronary artery; SS  subselective; TA 
TransAccess catheter.
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respect to surrounding structures, the nitinol needle was
extended into the myocardium (Fig. 4F). A 27-gauge
microinfusion (IntraLume) catheter was advanced through
the needle and into the myocardial tissue (Figs. 4G and
4H). Because the myocardial tissue is a potential space, and
without room for prolapse, all of the force for the otherwise
floppy IntraLume catheter is forward, essentially allowing
this catheter tip to become a drill capable of tunneling
through remote myocardium in plane with the needle
puncture (Fig. 3B).
The animals (n 6) were sacrificed at 0- (n 2), 14- (n
2), and 28-day (n 2) timepoints with IV potassium chloride
40 mEq overdose. All animals received cell/collagen biogel/
tissue dye except the negative control animal (collagen biogel/
tissue dye without cells), which was one of the animals
sacrificed at the 14-day timepoint. Accuracy was assessed by
correlating the dye stains identified by gross examination with
intended anatomic and fluoroscopic landmarks. Histologic
sections of the injection sites were subdivided into basal, mid-
and apical subsegments of the: 1) anterior, 2) lateral, 3)
anteroseptal, and 4) inferoseptal walls to allow for correlation
with the respective angiographic counterparts.
Tissue processing and staining. Portions of porcine myo-
cardium acquired from injection sites were frozen in Tissue
Tek optimal cutting temperature compound (Sakura Finetek
USA Inc., Torrance, California) and stored at 80°C for
subsequent histologic analysis. Histopathologic evaluation was
performed on 5-m cryosections of the tissue. Sections were
examined with a fluorescence microscope, using an NIB filter,
and subsequently stained with hematoxylin–eosin (H&E) and
Masson’s trichrome stains for study by light microscopy.
Immunohistochemical study of additional sections was per-
formed using anti-mouse GFP primary antibody (clone-20,
Sigma-Aldrich, St. Louis, Missouri) that cross-reacts with pig.
Binding was visualized by using a horseradish peroxidase
conjugated secondary antibody (Vector, Burlingame, Califor-
nia). Bound antibody was revealed by incubation of cryopre-
served sections in aminoethylcarbazole (Dako, Carpinteria,
California) or diaminobenzidine (Zymed, San Francisco, Cal-
ifornia). Sections were counterstained with hematoxylin solu-
tion (Sigma). Negative controls were checked by omitting the
primary antibody. Cryosections of skin from a GFP transgenic
mouse (Jackson Laboratory, Bar Harbor, Maine) were used as
a positive control for the immunohistochemical analysis. Given
the relatively poor expression of GFP in animals from each
timepoint, we focused histologic evaluation on the animal with
the highest percentage GFP expression at each timepoint.
RESULTS
Coronary venous access and direct myocardial injection was
successful in 100% (6/6) of the animals attempted. Access
was gained via the AIV approach to the basal-, mid-, and
apical-anterior, lateral, anteroseptal, and inferoseptal left
ventricular myocardium. Eighty-eight transvenous punc-
tures were performed (mean 14.6/animal). No death, car-
diac tamponade, or sustained arrhythmia occurred during
the procedure or the follow-up periods to time of sacrifice
(range 0 to 28 days).
Dye correlation on gross examination with angiographic
landmarks was 100% (Figs. 5 and 6). After cell recombination,
GFP expression determined by flow cytometry was relatively
poor in several animals (51% and 5% GFP% expression for the
two 28-day animals, 5% GFP% expression for the 14-day
animal, and 45% and 2% GFP% expression for the two acute
sacrifice animals). We suspect that this decrement in GFP%
expression is due to a disproportionate expansion of the initial
unlabeled cell fraction. The GFP-positive, autologous “donor”
bone marrow cells were determined to be present at the 0-,
14-, and 28-day timepoints, based on expression of signal on
fluorescence microscopy (Fig. 7) or density of expression above
background levels by immunohistochemistry, using light mi-
croscopy on sampled sections of targeted myocardium that
were demarcated with the biogel/tissue dye (Figs. 8 and 9).
Excessive fibrosis was not seen in comparison with control
areas of normal myocardium (Fig. 8). Determining cell prolif-
eration and transdifferentiation was outside the scope of this
study.
DISCUSSION
Conventional medical and surgical approaches are often
inadequate to treat patients with myocardial disease. Both
cell- and gene-based bioengineering approaches have been
proposed as potential alternate therapies to augment or
substitute damaged heart tissue (2,3). We present the initial
experience of a novel, catheter-based endovascular platform
for direct myocardial cell delivery using the coronary venous
system as a “roadmap to the heart” and a composite catheter
system to allow a direct, transvenous puncture and access to
the myocardium. We hypothesize that this method will
have advantages over presently utilized approaches.
Currently available methods for cardiovascular cell and/or
gene delivery have potential limitations. Direct surgical injec-
tion can provide a high level of substrate per unit area, but this
Figure 5. Cardiac magnetic resonance imaging of microlume infusion
catheter and injection site (gadolinium contrast enhancement in black)
performed in ex vivo pig heart.
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may result in high morbidity, and potential mortality, in the
target patient populations with recent MI or advanced CHF.
Futhermore, standard, transepicardial surgical approaches do
not grant free access to the septal wall and do not afford the
opportunity for real-time, contrast-enhanced assessment of the
microcirculation. The TransAccess catheter system shares the
advantages associated with surgical transepicardial access re-
garding accuracy and substrate deposition, but it only requires
local anesthesia at the femoral access site. In addition, the
septal wall is readily accessed, and “online” microcirculatory
assessment is readily available. Endoventricular approaches are
limited primarily by platform “stability.” Endoventricular cath-
eter systems do not rotate with the heart, which can minimize
target accuracy. The pressure of syringe injection with these
systems can be destabilizing and cause expulsion of the needle
tip from the myocardial interface. Needle withdrawal provides
an exit point for cells, gene therapy substrates, and so forth to
be released to the systemic circulation. Thinned myocardial
tissue (5 mm) is currently considered a contraindication
because of concerns for transepicardial perforation.
The TransAccess system overcomes these hurdles because
the needle and Microlume catheter are advanced in a coaxial
direction with the myocardial tissue. The catheter is there-
fore well seated deep within the heart muscle, rotates with
the heart, and is not subject to needle expulsion or cell loss
directly from the exit tract. Preliminary data suggest that
acute retention efficiency with this transvenous method and
fluoroscopic guidance is superior to electromechanical
mapping-guided endoventricular approaches (17). We hy-
pothesize that the deeper penetration into the myocardium
and the stability of the IntraLume microinfusion catheter
are largely responsible for this observation. In theory, the
risk of stroke from ventricular embolization or excessive
catheter manipulations and dwell time is reduced by access
and delivery from the venous side. Furthermore, thinned
tissue, in concept, is no more a limitation for IntraLume
injections than is standard open surgical approaches. We are
currently evaluating the second-generation CrossPoint
TransAccess catheter, which has a much more flexible shaft.
This new catheter system can easily track over a 0.014-inch
guide wire, obviating the need for the subselective catheter
component. The flexibility of this catheter is well suited for
subselective vein access, such as the middle cardiac vein
Figure 6. Gross examination of the myocardium demonstrated rows of
cell–biogel substrate, identified macroscopically with black tissue dye.
Figure 7. A bone marrow cell subpopulation was transduced with green
fluorescence protein (GFP) using vesiculostomatitis virus, expanded in
culture, and resuspended in a collgen biogel (A, in vitro imaging, 200
magnification), and demonstrated in vivo at 14 days (B, FITC conjugation,
200 magnification), and 28 days (C, direct green fluorescence, 400
magnification) in myocardial tissue demarcated by marker dye.
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(which parallels the posterior descending artery) for en-
hanced inferior wall access.
We used a collagen biogel as a cell “delivery vehicle.” The
role of biogels and biodegradable polymers is poorly under-
stood in cardiovascular applications. Our bias is that cell
packaging and delivery may be as important as the cell
sourcing for cardiovascular bioengineering applications (4–
7,18–21). We hypothesize that biogels and biodegradable
polymers may provide protection from physical compression
and lysis of the cells during their harsh transition to the
myocardium, provide architectural and nutritional support
during the engraftment process, and facilitate vascular
ingrowth and/or passive cell nutrition via diffusion pro-
cesses. Our experience with biodegradable polymers for the
application of cellular cardiomyoplasty is that they may
create ambiguity with the distinction of donor-host cellular
relationships, a factor that must be carefully considered and
circumvented when designing investigations in which such
relationships are the primary outcome measure. The utility
of such biopolymers to facilitate cellular cardiomyoplasty is
subject to ongoing investigation.
We identified what we believe to be autologous bone
marrow cell implants in normal porcine myocardium at 0-,
2-, and 4-week timepoints, based on GFP expression using
a variety of complementary histologic modalities in selected
myocardial sites that clearly retained the tissue dye and
biopolymer gel. Bone marrow cell subpopulations that are
adherent to uncoated flasks may contain mesenchymal stem
cells capable of multilineage potential through mesenchymal
pathways (muscle, bone, adipose, stroma) (15). Murine
investigations suggest that such bone marrow cell subpopu-
lations can be differentiated into a cardiomyocyte phenotype
in vitro and, perhaps, in vivo (22,23).
In addition, studies with conditioned media suggest that
bone marrow cell subpopulations may secrete high levels of
vascular endothelial growth factor and MCP-1, and poten-
tially can recruit vascular supply (8). Our cell population was
cultured in a similar fashion (15), but the cells were not
characterized prior to injection with cell surface markers,
and interspecies differences may certainly exist. This inves-
tigation was designed primarily to assess the catheter deliv-
ery system, and not transdifferentiation potential of our cell
source. We observed labeled cell orientation with the
porcine myocardium at the four-week timepoint. It is
interesting to speculate about the potential of this cell
Figure 8. Immunohistologic confirmatory analysis demonstrated evidence
of transplanted, autologous, “donor” bone marrow cells at 0 (A–D), 14
E–H), and 28 (I–L) days in targeted myocardial tissue demarcated by tissue
dye. Primary antibody versus green fluorescence protein (GFP), and
secondary antibody conjugated to HRP, DAB chromagen (A, E, I, red
arrows) were used to determine cell presence. Negative controls (B, F, J)
had nonspecific immunoglobulins used as primary antibody. Hematoxylin–
eosin (H&E) stains (C, G, K) show preserved myocardial architecture, and
minimal fibrosis is seen on trichrome staining (D, H, L). The animal that
received collagen biogel alone did not react nonspecifically to similar
antibody staining (M) and had similar preservation of myocardial archi-
tecture by H&E (N). Note the collagen biogel fragments (E, closed black
arrows) and interstitial biogel deposition (O, blue coloration, trichrome
stain). The black (M, N, O) are tissue dye remnants. Positive control for
the immunostain was assured using myocardial tissue from a transgenic
mouse, positive for GFP (C–D, E–H, K–P, 200 magnification; A–B,
I–J, 400 magnification).
4—————————————————————————————
population to transdifferentiate into myotubules as a milieu-
dependent process. However, this is clearly not proof of
concept and must be subject to rigorous investigation
specifically designed to assess such end points.
In summary, we present the initial experience of intra-
cardiac, autologous bone marrow cell transplantation with a
new catheter-based system that allows direct myocardial
access with IVUS-guided needle punctures through the
coronary venous system and infusion catheter placement
into remote myocardium. This method of cell delivery may
have potential advantages over currently available ap-
proaches, and it provides a new, stable platform for cardio-
vascular bioengineering therapies. Autologous cell popula-
tions from adult bone marrow may have a potential role for
in vivo tissue engineering strategies for cardiac angiomyo-
genesis.
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